Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Sabouret

Showing results (21-30 of 131) with videos related to

Pageof 14
Sort By:
European Cardiology|November 15, 2021
Women and Diabetes: Preventing Heart Disease in a New Era of TherapiesGiuseppe Galati, Pierre Sabouret, Olga Germanova, et al.
European Heart Journal Open|September 19, 2022
Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?Pierre Sabouret, Denis Angoulvant, Christopher P Cannon, et al.
Journal of Cardiovascular Pharmacology|July 24, 2023
Advanced Imaging Guiding Early Sodium-Glucose Cotransporter-2 Inhibitor Therapy: An Outlook to the Future?Stefano Figliozzi, Pierre Sabouret, Giuseppe Biondi-Zoccai, et al.
Cardiology|May 19, 2026
Main Lessons of the Recent Andexanet WithdrawalPierre Sabouret, Dan Atar, Marco Bernardi, et al.
European Heart Journal|April 16, 2023
Modulation and personalization of therapy after acute coronary syndromes: the road to precisionPierre Sabouret, Giuseppe Biondi-Zoccai, Maciej Banach, et al.
International Journal of Cardiology|February 15, 2025
STARTing a new path in cardiovascular prevention: Lessons from SELECT and real-world evidence on Semaglutide in obesity-driven riskGiuseppe Andò, Giulia Cavolina, Alessio Villari, et al.
European Heart Journal|October 4, 2023
What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectivesPierre Sabouret, Fiona Ecarnot, Salvatore De Rosa, et al.
Current Atherosclerosis Reports|July 4, 2024
Cardiovascular Risk Estimation and Stratification Among Individuals with HypercholesterolemiaGiosiana Bosco, Reed Mszar, Salvatore Piro, et al.
Archives of Medical Science : AMS|April 10, 2023
Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?Marco Bernardi, Luigi Spadafora, Mattia Galli, et al.
Clinical Cardiology|June 15, 2016
Prasugrel Use in Real Life: A Report From the Outpatient Setting in FrancePierre Sabouret, Magali Taiel-Sartral, Florence Chartier, et al.
Pageof 14

Showing results (21-30 of 131) with videos related to

Sort By:
Pageof 14
European Cardiology|November 15, 2021
Women and Diabetes: Preventing Heart Disease in a New Era of TherapiesGiuseppe Galati, Pierre Sabouret, Olga Germanova, et al.
European Heart Journal Open|September 19, 2022
Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?Pierre Sabouret, Denis Angoulvant, Christopher P Cannon, et al.
Journal of Cardiovascular Pharmacology|July 24, 2023
Advanced Imaging Guiding Early Sodium-Glucose Cotransporter-2 Inhibitor Therapy: An Outlook to the Future?Stefano Figliozzi, Pierre Sabouret, Giuseppe Biondi-Zoccai, et al.
Cardiology|May 19, 2026
Main Lessons of the Recent Andexanet WithdrawalPierre Sabouret, Dan Atar, Marco Bernardi, et al.
European Heart Journal|April 16, 2023
Modulation and personalization of therapy after acute coronary syndromes: the road to precisionPierre Sabouret, Giuseppe Biondi-Zoccai, Maciej Banach, et al.
International Journal of Cardiology|February 15, 2025
STARTing a new path in cardiovascular prevention: Lessons from SELECT and real-world evidence on Semaglutide in obesity-driven riskGiuseppe Andò, Giulia Cavolina, Alessio Villari, et al.
European Heart Journal|October 4, 2023
What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectivesPierre Sabouret, Fiona Ecarnot, Salvatore De Rosa, et al.
Current Atherosclerosis Reports|July 4, 2024
Cardiovascular Risk Estimation and Stratification Among Individuals with HypercholesterolemiaGiosiana Bosco, Reed Mszar, Salvatore Piro, et al.
Archives of Medical Science : AMS|April 10, 2023
Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?Marco Bernardi, Luigi Spadafora, Mattia Galli, et al.
Clinical Cardiology|June 15, 2016
Prasugrel Use in Real Life: A Report From the Outpatient Setting in FrancePierre Sabouret, Magali Taiel-Sartral, Florence Chartier, et al.
Pageof 14